Nicole Murphy - 01 Aug 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Pharm Ops and Tech
Signature
/s/ Wendell Taylor, attorney in fact for Nicole Murphy
Issuer symbol
BIIB
Transactions as of
01 Aug 2022
Net transactions value
-$66,754
Form type
4
Filing time
03 Aug 2022, 17:40:39 UTC
Previous filing
05 Apr 2022
Next filing
06 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +255 +13% $0.000000 2,170 01 Aug 2022 Direct F1
transaction BIIB Common Stock Tax liability $15,904 -76 -3.5% $209.26 2,094 01 Aug 2022 Direct
transaction BIIB Common Stock Options Exercise $0 +825 +39% $0.000000 2,919 01 Aug 2022 Direct
transaction BIIB Common Stock Tax liability $50,850 -243 -8.3% $209.26 2,676 01 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Other $0 -299 -54% $0.000000 255 01 Aug 2022 Common Stock 299 $0.000000 Direct F2, F3
transaction BIIB Restricted Stock Unit Options Exercise $0 -255 -100% $0.000000* 0 01 Aug 2022 Common Stock 255 $0.000000 Direct F3
transaction BIIB Restricted Stock Unit Options Exercise $0 -825 -100% $0.000000* 0 01 Aug 2022 Common Stock 825 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan.
F2 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
F3 This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)).
F4 This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022.